JBIO ▼ -0.1% - Jade Biosciences, Inc.
$JBIO - Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-? Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
30-SEP-2026 07:00 AM ET
Share this post
More filings for $JBIO
JBIO ▼ -0.0% - Jade Biosciences, Inc.Sep 1, 2026JBIO - Jade Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$JBIO SEC Filing Update (17-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 17, 2026$JBIO SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 8, 2026$JBIO SEC Filing Update (09-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 9, 2026
View full $JBIO filing history →💬 Comments
Loading comments…
Leave a comment